Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic cancer.

On Feb. 26, the companies said that first-line maintenance treatment with Lynparza olaparib met the primary endpoint of improving progression-free survival (PFS) vs. placebo in the Phase III POLO trial to treat germline BRCA-mutated metastatic pancreatic cancer. Specific data were not announced, but the partners said they plan to present full data from the trial at a medical meeting and will meet with global regulatory authorities as soon as possible...